Josiah Aldrup
Psychiatric/Mental Health · Huntsville, ALNPI 1184165748
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Alkermes, Inc. at 33.2% of the total. 2025 is the largest year on record at $2,762, 5.9 times the $471 reported in 2021.
Across 276 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- AbbVie$800
- Johnson & Johnson$628
- Teva Pharmaceuticals USA, Inc.$574
- Neurocrine Biosciences, Inc.$487
- Otsuka America Pharmaceutical, Inc.$440
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$581%
- Food & beverage$6,45795%
- Education$2824%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 85 | $2,257 |
| AbbVie | 28 | $800 |
| Johnson & Johnson | 19 | $628 |
| Teva Pharmaceuticals USA, Inc. | 21 | $574 |
| Neurocrine Biosciences, Inc. | 19 | $487 |
| Otsuka America Pharmaceutical, Inc. | 21 | $440 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $422 |
| Supernus Pharmaceuticals, Inc. | 15 | $318 |
| E.r. Squibb & Sons, L.L.C. | 6 | $201 |
| Vanda Pharmaceuticals Inc. | 14 | $194 |
| Collegium Pharmaceutical, Inc. | 1 | $124 |
| Indivior Inc. | 5 | $84 |
| BD | 1 | $58 |
| Axsome Therapeutics, Inc. | 3 | $52 |
| Corium, LLC | 5 | $40 |
| Lundbeck LLC | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $17 |
| Merck | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Pfizer | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,376
- ARISTADA$954
- ARISTADA INITIO$239
- INVEGA SUSTENNA$143
- REXULTI$125
- JORNAY PM$124
- VRAYLAR$118
- COBENFY$118
How this compares
$6,797 in reported general payments places this provider in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 48 | $376,064 |
| Austedo XrDeutetrabenazine | 42 | $270,282 |
| Invega SustennaPaliperidone Palmitate | 90 | $262,358 |
| VraylarCariprazine Hcl | 122 | $173,439 |
| Abilify MaintenaAripiprazole | 53 | $157,401 |
| AristadaAripiprazole Lauroxil | 29 | $97,406 |
| Chlorpromazine Hcl | 233 | $51,103 |
| UzedyRisperidone | 18 | $49,242 |
| Risperdal ConstaRisperidone Microspheres | 22 | $44,008 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $38,389 |
| RexultiBrexpiprazole | 41 | $35,275 |
| TrintellixVortioxetine Hydrobromide | 43 | $31,282 |
| Divalproex Sodium ErDivalproex Sodium | 481 | $27,590 |
| Lupron DepotLeuprolide Acetate | 13 | $23,878 |
| FanaptIloperidone | 12 | $23,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy | $574 | $695,588108 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $628 | $306,366112 claims |
| AbbVieVraylar, Lupron Depot | $800 | $197,317135 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $440 | $192,67694 claims |
| Alkermes, Inc.Aristada, Lybalvi | $2,257 | $135,79547 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $194 | $23,09012 claims |
| Lilly USA, LLCOlanzapine | $16 | $16,279678 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $4,493462 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Huntsville
- Ian KinzerHuntsville$15K
- Narae PhulongphiaHuntsville$9K
- Sharon WrightHuntsville$6K
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
- John HayesMobile$30K
- Logan ThrasherHoover$22K
- Anthony PhillipsHelena$15K
- Latisha AliHoover$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.